What question did this study set out to answer?

To evaluate the margin-negative (R0) resection rate following neoadjuvant FOLFIRINOX combined with losartan and subsequent chemoradiotherapy in locally advanced pancreatic cancer.

May 30, 2019JAMA OncologyOpen Access

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer

View Full Paper

Ask AI

Bookmark

To evaluate the margin-negative (R0) resection rate following neoadjuvant FOLFIRINOX combined with losartan and subsequent chemoradiotherapy in locally advanced pancreatic cancer.
Conducted a single-arm phase 2 clinical trial (NCT01821729) among 49 patients with previously untreated locally advanced unresectable pancreatic cancer at a single academic hospital with a median follow-up of 17.1 months.
Administered up to 8 cycles of FOLFIRINOX and losartan, followed by short-course proton chemoradiotherapy for resectable tumors or long-course chemoradiotherapy for persistent vascular involvement prior to surgery.
Surgical resection was attempted in 42 of 49 patients (86%), with R0 resection successfully achieved in 34 of 49 patients (69%; 95% CI, 55%-82%).
Overall median progression-free survival was 17.5 months (95% CI, 13.9-22.7) and median overall survival was 31.4 months (95% CI, 18.1-38.5).
Among patients who underwent surgical resection, median progression-free survival reached 21.3 months (95% CI, 16.6-28.2) and median overall survival reached 33.0 months (95% CI, 31.4 to not reached).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase 2 clinical trial reveals high R0 resection rates in locally advanced pancreatic cancer, highlighting the efficacy of total neoadjuvant therapy.

Cite This Study

Murphy et al. (2019) studied this question.

synapsesocial.com/papers/6a836ef37ea419b390a6cf5f https://doi.org/10.1001/jamaoncol.2019.0892

View Full Paper

Ask AI

Bookmark

Implication

Phase 2 clinical trial reveals high R0 resection rates in locally advanced pancreatic cancer, highlighting the efficacy of total neoadjuvant therapy.

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer

Key Points

Discussion

Implication

Cite This Study

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider